Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes
Year: 2013
Type: article
Abstract: OBJECTIVE: Type 2 diabetes increases cardiovascular risk. We examined lipid profiles and inflammatory markers in 699 youth with recent-onset type 2 diabetes in the TODAY clinical trial and compared changes across treatment groups: metformin alone (M), metformin plus rosiglitazone (M+R), and metformin plus intensive lifestyle program (M+L). RESEARCH DESIGN AND METHODS: Multiethnic youth with type 2 diabetes received M, M+R, or M+L. Statin drugs were begun for LDL cholesterol (LDL) ≥ 130 mg/dL or triglycerides ≥ 300 mg/dL. Lipids, apolipoprotein B (apoB), LDL particle size, high-sensitivity c-reactive protein (hsCRP), homocysteine, plasminogen activator inhibitor-1 (PAI-1), and HbA1c were measured over 36 months or until loss of glycemic control. RESULTS: LDL, apoB, triglycerides, and non-HDL cholesterol (HDL) rose over 12 months and then stabilized over the next 24 months. Participants with LDL ≥ 130 mg/dL or using LDL-lowering therapy increased from 4.5 to 10.7% over 36 months, while 55.9% remained at LDL goal (<100 mg/dL) over that time. Treatment group did not impact LDL, apoB, or non-HDL. Small dense LDL (particle size, ≤ 0.263 relative flotation rate) was most common in M. Triglycerides were lower in M+L than M, and M+L attenuated the negative effect of hyperglycemia on triglycerides and HDL in females. hsCRP, PAI-1, and homocysteine increased over time. However, hsCRP was lower in M+R compared with M or M+L. CONCLUSIONS: Dyslipidemia and chronic inflammation were common in youth with type 2 diabetes and worsened over time. Diabetes treatment, despite some treatment group differences in lipid and inflammatory marker change over time, is generally inadequate to control this worsening risk.
Source: Diabetes Care
DOI: 10.2337/dc12-2388
Author: TODAY Study Group
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: type 2 diabetes in youth, dyslipidemia, cardiovascular risk, chronic inflammation, LDL cholesterol, apolipoprotein B, small dense LDL, triglycerides, non-HDL cholesterol, high-sensitivity C-reactive protein, plasminogen activator inhibitor-1, homocysteine, metformin, rosiglitazone, intensive lifestyle intervention, statin therapy
Open Access status: hybrid
Awards: General Clinical Research Center, Management of Pediatric Type 2 Diabetes Mellitus, Multi-Center Study of the Treatment of T2DM in Youth, Case Western Reserve University/Cleveland Clinic CTSA (UL1), Southern California Clinical and Translational Science Institute, Harvard Clinical and Translational Science Center (UL1), General Clinical Research Center, University of Pittsburgh Clinical and Translational Science Institute, Type 2 Diabetes in Youth: Beta Cell Preservation, Treatment Alternatives in Pediatric Type 2 Diabetes, TODAY2 Phase 2 (T2P2): Long-Term Post-Intervention Follow-Up, Institutional Clinical and Translational Science Award, University of Pittsburgh Clinical and Translational Science Institute, General Clinical Research Center, G606898507, General Clinical Research Center, General Clinical Research Center, Washington University Institute of Clinical and Translational Sciences, Washington University Institute of Clinical and Translational Sciences (UL1), Yale University Clinical and Translational Science Award Program, General Clinical Research Center, Clinical and Translational Science Collaborative of Cleveland, GENERAL CLINICAL RESEARCH CENTER, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W2622955276
